How do you pay?

How to pay the least

Ask for the cash price

Lumakras

We didn’t find one.

What to do

  1. Ask your pharmacy for Lumakras’s cash price, and one or two other pharmacies too.
  2. Lumakras’s savings card works only with insurance from a job or one you bought.

Other ways

Free from the maker, if you qualify Amgen Safety Net Foundation. Amgen Safety Net Foundation income requirements are based on a percentage of the Federal Poverty Level, adjusted for household size. Or call 1-800-932-3060.

See if you qualify 

Compare every option

Brand name

Lumakras, the original

Cash priceAsk the pharmacy
Ways to save on Lumakras

The maker’s card

Amgen SupportPlus Co-Pay Program

Savings card from Amgen

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a prescription

Sign up on lumakras.com 

Or call 1-866-264-2778.

In the maker’s words

“If you have private or commercial insurance that you get from your employer or buy directly from a health insurance company, you may be eligible to pay as little as $0 for your prescription.”

From the maker’s offer on lumakras.com, checked November 17, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized generic

There isn’t one.

Not soldThere isn’t one

Regular generic

We didn’t find one.

Not soldNone found

What it’s used for

What the FDA label says

LUMAKRAS is an inhibitor of the RAS GTPase family indicated for:

KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy.

This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC)

In combination with panitumumab, for the treatment of adult patients with KRAS G12C-mutated mCRC as determined by an FDA approved-test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.

Source: the FDA label for Lumakras (Amgen, Inc), November 3, 2026. Full label on DailyMed 

Good to know

  • “Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
  • Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
  • Don’t stop or change a medicine without talking to your pharmacist or prescriber.